Jan. 15, 2026 — San Francisco Sichuan Biokin Pharmaceutical Co., Ltd., affiliate and partner of Redmond, Washington-based SystImmune Inc., presented its oncology pipeline during the APAC Track at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday at 11:30 a.m. PST in Mission Bay.
The presentation highlighted Biokin’s bi-specific and multi-specific antibodies and antibody-drug conjugates (ADCs) targeting solid tumors and hematologic cancers, according to an official press release issued by SystImmune on January 13. A live webcast was available via the conference platform at jpmorgan.metameetings.net, with replay and presentation materials promised on SystImmune’s investor page post-event.
SystImmune, a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, confirmed Biokin as its China-based affiliate in the announcement mirrored on its news page. The conference agenda listed Sichuan Biokin Pharmaceutical Co., Ltd., at 11:00 a.m., aligning closely with the announced slot.
Presenter Jie D’Elia shared excitement ahead of the event in a LinkedIn post on January 14:
Thrilled to present Biokin/SystImmune’s innovative cancer therapeutics at the J.P. Morgan Healthcare Conference tomorrow!
Biokin’s pipeline includes partnerships such as with Bristol Myers Squibb on the ADC iza-bren, emphasizing oncology ADCs, per the press release.
The announcement garnered standard wire distribution on platforms including Yahoo Finance, Moomoo, and Barchart, but no major independent media coverage or social media buzz was noted amid the conference’s 400+ presentations.
As of January 17, no post-event slides or transcripts were available on SystImmune’s website. Updates can be checked on the company’s investor resources.
